Literature DB >> 7926343

Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes.

J Ruiz1, J Thillet, T Huby, R W James, D Erlich, P Flandre, P Froguel, J Chapman, P Passa.   

Abstract

Non-insulin-dependent diabetes mellitus (NIDDM) is a strong and independent risk factor for coronary heart disease. We assessed the potential relationship between plasma Lp(a) levels, apo(a) phenotypes and coronary heart disease in a population of NIDDM patients. Seventy-one patients with coronary heart disease, who previously have had transmural myocardial infarction, or significant stenosis on coronary angiography, or positive myocardial thallium scintigraphy, or in combination, were compared with 67 patients without coronary heart disease, who tested negatively upon either coronary angiography, myocardial thallium scintigraphy or a maximal exercise test. The prevalence of plasma Lp(a) levels elevated above the threshold for increased cardiovascular risk (> 0.30 g/l) was significantly higher (p = 0.005) in patients with coronary heart disease (33.8%) compared to the control group (13.4%). The relative risk (odds ratio) of coronary heart disease among patients with high Lp(a) concentrations was 3.1 (95% confidence interval, 1.31-7.34; p = 0.01). The overall frequency distribution of apo(a) phenotypes differed significantly between the two groups (p = 0.043). However, the frequency of apo(a) isoforms of low apparent molecular mass (< or = 700 kDa) was of borderline significance (p = 0.067) between patients with or without coronary heart disease (29.6% and 16.4%, respectively). In this Caucasian population of NIDDM patients, elevated Lp(a) levels were associated with coronary heart disease, an association which was partially accounted for by the higher frequency of apo(a) isoforms of small size. In multivariate analyses, elevated levels of Lp(a) were independently associated with coronary heart disease (odds ratio 3.48, p = 0.0233).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926343     DOI: 10.1007/bf00403377

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  34 in total

1.  Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis.

Authors:  C Lackner; E Boerwinkle; C C Leffert; T Rahmig; H H Hobbs
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.

Authors:  J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

3.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.

Authors:  L A Carlson; A Hamsten; A Asplund
Journal:  J Intern Med       Date:  1989-10       Impact factor: 8.989

4.  Serum lipoprotein(a) in patients with diabetes mellitus.

Authors:  F R Heller; J Jamart; P Honore; G Derue; V Novik; L Galanti; A Parfonry; J C Hondekijn; M Buysschaert
Journal:  Diabetes Care       Date:  1993-05       Impact factor: 19.112

5.  Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM.

Authors:  G Velho; D Erlich; E Turpin; D Néel; D Cohen; P Froguel; P Passa
Journal:  Diabetes Care       Date:  1993-05       Impact factor: 19.112

6.  Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?

Authors:  L Hervio; M J Chapman; J Thillet; S Loyau; E Anglés-Cano
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

7.  Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.

Authors:  F S Nielsen; A I Voldsgaard; M A Gall; P Rossing; E Hommel; P Andersen; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

8.  Asymptomatic myocardial ischemia in diabetic patients.

Authors:  R W Nesto; R T Phillips
Journal:  Am J Med       Date:  1986-04-30       Impact factor: 4.965

9.  Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor.

Authors:  T Keilani; W A Schlueter; M L Levin; D C Batlle
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

10.  The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease.

Authors:  G Assmann; H Schulte
Journal:  Am Heart J       Date:  1988-12       Impact factor: 4.749

View more
  8 in total

Review 1.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

2.  Lipoprotein(a) and risk of type 2 diabetes.

Authors:  Samia Mora; Pia R Kamstrup; Nader Rifai; Børge G Nordestgaard; Julie E Buring; Paul M Ridker
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

Review 3.  The role of non-LDL:non-HDL particles in atherosclerosis.

Authors:  Jere P Segrest
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

4.  Lipoprotein (a) and vascular disease in diabetic patients.

Authors:  R W James; M Boemi; C Sirolla; L Amadio; P Fumelli; D Pometta
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

5.  Lipoprotein(a) and cardiovascular disease in diabetic patients.

Authors:  Qibin Qi; Lu Qi
Journal:  Clin Lipidol       Date:  2012-08

6.  Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism.

Authors:  Carmine Gazzaruso; Adriana Garzaniti; Stefano Giordanetti; Colomba Falcone; Pietro Fratino
Journal:  Cardiovasc Diabetol       Date:  2002-11-22       Impact factor: 9.951

7.  Urban-rural differences in atherogenic dyslipidaemia (URDAD Study): a retrospective report on diabetic and non-diabetic subjects of Northern India.

Authors:  Poonam Agrawal; Varikasuvu Seshadri Reddy; Himanshu Madaan; Surajeet Kumar Patra; Renu Garg
Journal:  J Health Popul Nutr       Date:  2014-09       Impact factor: 2.000

8.  Insulin resistance contributes more to the increased risk for diabetes development in subjects with low lipoprotein(a) level than insulin secretion.

Authors:  Eun-Jung Rhee; Jung Hwan Cho; Da Young Lee; Hyemi Kwon; Se Eun Park; Cheol-Young Park; Ki-Won Oh; Sung-Woo Park; Won-Young Lee
Journal:  PLoS One       Date:  2017-05-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.